Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2443988 | 0.85 | GAA (0.45) | KDM4EHSD17B10MAPTGAATSHR | |
| SCHEMBL7355446 | 0.85 | HTT (0.46) | KDM4EHSD17B10MAPTGAAMAPK1 | |
| SCHEMBL4286291 | 0.84 | KDM4E (0.43) | KDM4EHSD17B10MAPTTSHRMAPK1 | |
| SCHEMBL182820 | 0.83 | ALDH1A1 (0.49) | KDM4EHSD17B10MAPTTSHRPOLB | |
| SCHEMBL1205875 | 0.83 | TDP1 (0.51) | KDM4EHSD17B10MAPTGAATSHR | |
| SCHEMBL9827992 | 0.83 | TSHR (0.49) | HSD17B10MAPTGAATSHRPOLB | |
| SCHEMBL130031 | 0.82 | TSHR (0.44) | KDM4EHSD17B10MAPTGAATSHR | |
| SCHEMBL182862 | 0.82 | PLK1 (0.49) | HSD17B10MAPTGAATSHRMAPK1 | |
| SCHEMBL21268326 | 0.82 | EPHX2 (0.38) | KDM4EHSD17B10TSHRPOLBSLC6A3 | |
| SCHEMBL182690 | 0.81 | MKNK1 (0.40) | KDM4EGAATSHRPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152271-A1 | GAK MODULATORS AS ANTIVIRALS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-06-01 | — | — | US | claimed |
| EP-3016958-A1 | NOVEL GAK MODULATORS | Katholieke Universiteit Leuven (BE) | 2016-05-11 | — | — | EP | claimed |
| US-20160122364-A1 | NOVEL GAK MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-05-05 | — | — | US | claimed |
| WO-2016012536-A1 | GAK MODULATORS AS ANTIVIRALS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-01-28 | — | — | WO | claimed |
| US-9139546-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2015-09-22 | — | — | US | claimed |
| WO-2015001076-A1 | NOVEL GAK MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-01-08 | — | — | WO | claimed |
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-08-25 | — | — | US | claimed |
| US-7888365-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-02-15 | — | — | US | claimed |
| EP-2131655-A2 | TRI-ARYL/HETEROAROMATIC CANNABINOIDS AND USE THEREOF | The University of Tennessee Research Foundation (US) | 2009-12-16 | — | — | EP | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | claimed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-09-25 | — | — | US | claimed |
| WO-2008109027-A2 | TRI-ARYL/HETEROAROAROMATIC CANNABINOIDS AND USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2008-09-12 | — | — | WO | claimed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| US-5756799-A | HYDROGENATION CATALYSTS FOR OLEFINS USING RHODIUM CATALYST COMPLEXES | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 1998-05-26 | — | — | US | claimed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-4824834-A | TREATING GOUT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0269859-A2 | Pyrazolotriazine compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | KDM4E 649/4885HSD17B10 1268/4885MAPT 4544/4885 |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | CNR1, CNR2, OPRM1 | KDM4E 1931/4885HSD17B10 2688/4885MAPT 2162/4885 |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | KDM4E 1674/4885HSD17B10 1064/4885MAPT 4105/4885 |
| US-20160122364-A1 | NOVEL GAK MODULATORS | GAK, CAMKK2, GRK3 | KDM4E 2604/4885HSD17B10 3906/4885MAPT 616/4885 |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | CNR1, CNR2, OPRM1 | KDM4E 1931/4885HSD17B10 2688/4885MAPT 2162/4885 |
| US-20170152271-A1 | GAK MODULATORS AS ANTIVIRALS | GAK, IRF3, EIF2AK2 | KDM4E 2152/4885HSD17B10 4459/4885MAPT 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.